Prestige announces licensing agreement with Cipla, granting Cipla exclusive rights to distribute and market Prestige’s TmAb biosimilar in emerging markets.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Dec 23, 2018
Prestige announces licensing agreement with Cipla, granting Cipla exclusive rights to distribute and market Prestige’s TmAb biosimilar in emerging markets.
By Bioblast Editor | Dec 22, 2018
Fuji Pharma announces acquisition of 4.2% stake in Alvotech for roughly $50 million.
By Bioblast Editor | Dec 20, 2018
The NHS announces negotiations for the supply of adalimumab biosimilars have concluded with Amgen, Biogen, Mylan, Sandoz and AbbVie. This deal is predicted to save the NHS £300M per year.
By Bioblast Editor | Dec 20, 2018
Biocon announces EU marketing authorisation for biosimilar trastuzumub, Ogivri®. Ogivri® is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastic gastric cancer.
By Bioblast Editor | Dec 20, 2018
FDA approves TmAb biosimilar for the treatment of HER2-positive breast cancer. Herzuma® is the second TmAb biosimilar to be approved in the US. Celltrion is currently defending the biosimilar against Genentech, and while Genentech and Pfizer have reached a settlement, Cellt...
By Bioblast Editor | Dec 19, 2018
Xbrane submits first CTA to FDA for clinical trials of ranibizumab biosimilar candidate, Xlucane®. The Phase III trials will be conducted in patients with wet form of age-related macular degeneration.
By Bioblast Editor | Dec 17, 2018
NeuClone announces that it has biosimilar pertuzumab in preclinical development.
By Bioblast Editor | Dec 15, 2018
French study supports the use of Remsima® in the treatment of Crohn’s disease, showing equivalency to reference product in safety and effectiveness.
By Bioblast Editor | Dec 14, 2018
PBAC releases results from November PBAC meeting. The PBAC recommended Alphapharm’s Fulphila® for listing on the PBAC for all indications with “A” flagging. Fulphila® and Amgen’s Neulasta® and Ristempa® brands of pegfilgrastim are now considered equ...
SUBSCRIBE TO PEARCE IP